gabexate has been researched along with Hematologic Neoplasms in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated clinical outcomes of disseminated intravascular coagulation (DIC) in patients with hematological malignancies treated with synthetic protease inhibitors (SPIs) and compared the effects of gabexate mesilate (FOY) and nafamostat mesilate (FUT)." | 7.91 | Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. ( Ashizawa, M; Fujiwara, SI; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Ohmori, T; Sato, K; Sugimoto, M; Toda, Y; Umino, K; Yamamoto, C; Yamasaki, R, 2019) |
| "We evaluated clinical outcomes of disseminated intravascular coagulation (DIC) in patients with hematological malignancies treated with synthetic protease inhibitors (SPIs) and compared the effects of gabexate mesilate (FOY) and nafamostat mesilate (FUT)." | 3.91 | Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. ( Ashizawa, M; Fujiwara, SI; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Ohmori, T; Sato, K; Sugimoto, M; Toda, Y; Umino, K; Yamamoto, C; Yamasaki, R, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Minakata, D | 1 |
| Fujiwara, SI | 1 |
| Ikeda, T | 1 |
| Kawaguchi, SI | 1 |
| Toda, Y | 1 |
| Ito, S | 1 |
| Ochi, SI | 1 |
| Nagayama, T | 1 |
| Mashima, K | 1 |
| Umino, K | 1 |
| Nakano, H | 1 |
| Yamasaki, R | 1 |
| Morita, K | 1 |
| Kawasaki, Y | 1 |
| Sugimoto, M | 1 |
| Yamamoto, C | 1 |
| Ashizawa, M | 1 |
| Hatano, K | 1 |
| Sato, K | 1 |
| Oh, I | 1 |
| Ohmine, K | 1 |
| Muroi, K | 1 |
| Ohmori, T | 1 |
| Kanda, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)[NCT04352400] | Phase 2/Phase 3 | 256 participants (Anticipated) | Interventional | 2021-06-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for gabexate and Hematologic Neoplasms
| Article | Year |
|---|---|
Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies.
Topics: Adult; Anticoagulants; Benzamidines; Disseminated Intravascular Coagulation; Female; Gabexate; Guani | 2019 |